<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379729</url>
  </required_header>
  <id_info>
    <org_study_id>BK_TX_07</org_study_id>
    <nct_id>NCT01379729</nct_id>
  </id_info>
  <brief_title>Bet Cell Therapy in Diabetes Type 1</brief_title>
  <official_title>Functional Survival of Beta Cell Allografts After Transplantation in the Peritoneal Cavity of Non-uremic Type 1 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ-VUB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AZ-VUB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary outcome measurement is a parameter of functional beta cell mass at 6 months PT.
      Functional beta-cell mass will be calculated using the AUC/min between 150 and 160 min during
      hyperglycemic clamp at 180 mg/dl.

      The investigators hypothesize that functional beta-cell mass will be more than 20% compared
      to healthy controls.

      Secondary outcome measurements:

      Functional beta-cell mass at 2,12,18,24,36,48 and 60 months PT.

      The investigators will also compare at 2, 6,12, 24,36,48 and 60 months the changes against
      base-line (base-line = before first intraperitoneal transplantation):

        -  metabolic control

        -  safety parameters

        -  episodes of hypoglycemia

        -  islet cell autoantibodies, lymphocyte subsets, T-cell reactivity against auto- and
           alloantigens using pre-transplant measurements as base-line The investigators
           hypothesize that metabolic control and prevalence of hypoglycemia, will be significantly
           improved till PT month 12.

      Histopathology of a biopsy specimen of the human intraperitoneal beta cell implant, at time
      of the second implant. Comparison with composition of graft, identification of
      microenvironment of host origin and correlation with functional assessment will be performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recipients with loss of long-term function after intraportal implantation (Group A)

        1. To implant an alginate embedded human beta cell graft in a &quot;therapeutic&quot; dose in the
           intraperitoneal cavity of type 1 diabetic patients under immunosuppression with
           tacrolimus/MMF.

        2. To obtain histopathology of a biopsy specimen of the intraperitoneal human beta cell
           implant.

        3. To assess the safety profile, metabolic and immune effects of alginate embedded implants
           in the intraperitoneal cavity.

           In patients that are candidates for islet cell transplantation (Group B)

        4. To implant an alginate embedded human beta cell graft in a &quot;therapeutic&quot; dose in
           intraperitoneal cavity of type 1 diabetic patients under immunosuppression with
           tacrolimus/MMF.

        5. To obtain histopathology of a biopsy specimen of the intraperitoneal human beta cell
           implant

        6. To assess the safety profile, metabolic and immune effects of alginate embedded implants
           in the intraperitoneal cavity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measurement is a parameter of functional beta cell mass at 6 months PT. Functional beta-cell mass will be calculated using the AUC/min between 150 and 160 min during hyperglycemic clamp at 180 mg/dl.</measure>
    <time_frame>6 months PT.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional beta-cell mass at 2,12,18,24,36,48 and 60 months PT.</measure>
    <time_frame>60 months</time_frame>
    <description>Functional beta-cell mass at 2,12,18,24,36,48 and 60 months PT.
The investigators will also compare at 2, 6,12, 24,36,48 and 60 months the changes against base-line (base-line = before first intraperitoneal transplantation):
metabolic control
safety parameters
episodes of hypoglycemia
islet cell autoantibodies, lymphocyte subsets, T-cell reactivity against auto- and alloantigens using pre-transplant measurements as base-line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional beta-cell mass at 2,12,18,24,36,48 and 60 months PT.</measure>
    <time_frame>60 months</time_frame>
    <description>Functional beta-cell mass at 2,12,18,24,36,48 and 60 months PT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline</measure>
    <time_frame>60 months</time_frame>
    <description>The investigators will also compare at 2, 6,12, 24,36,48 and 60 months the changes against base-line (base-line = before first intraperitoneal transplantation):
metabolic control
safety parameters
episodes of hypoglycemia
islet cell autoantibodies, lymphocyte subsets, T-cell reactivity against auto- and alloantigens using pre-transplant measurements as base-line</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with loss of long-term function after intraportal implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients that are candidates for islet cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transplantation of encapsulated beta cells.</intervention_name>
    <description>Implantation of a therapeutical dose of encapsulated beta cells.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>encapsulated beta cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transplantation of encapsulated beta cells.</intervention_name>
    <description>Implantation of a therapeutical dose of encapsulated beta cells.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>encapsulated beta cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group A:

        Patients with loss of long-term function after intraportal implantation (- Patients with
        type 1 insulin-dependent diabetes who received two intraportal implantations &gt; 12 months
        ago.

          -  Random C-peptide between 0.09 and 0.5 ng/dl (glycemia between 100 and 200 mg/dl)

          -  Cooperative and reliable patient giving informed consent by signature

        Group B:

        Patients that are candidates for islet cell transplantation - age 18-65 years, male or
        female, Caucasian or not; only subjects &lt; 50 yrs will be allocated to the rituximab
        treatment arm

          -  body weight &lt; 100 kg; patients with a bodyweight of &lt; 80kg, will receive priority

          -  patients with a BMI ≤ 27 kg/m2 will receive priority

          -  Type 1 insulin-dependent diabetes

          -  C-peptide &lt; 0.07 nmol/l (&lt; 0.2 µg/l) 6 min. after glucagon IV (1mg) (glycemia &gt; 180
             mg/dl)

          -  Intensive insulin therapy for more than two years, patients with insulin pump during
             at least 2 months before inclusion will receive priority

          -  Patients should have at least one of the following chronic complications of diabetes:

               -  albuminuria 30-1000mg/ 24hrs on 3 separate determinations (&gt;1 month) outside an
                  episode of illness, despite intake of ACE inhibitors; mean systolic blood
                  pressure should be under 130 mmHg and mean diastolic blood pressure under 85
                  mmHg, when measured at home with ambulatory BP monitoring

               -  moderate or severe non-proliferative or proliferative retinopathy

               -  hypoglycemic unawareness

          -  Cooperative and reliable patient giving informed consent by signature

        Exclusion Criteria:

          -  Women of reproductive age

               -  Smoker

               -  EBV antibody negativity

               -  HIV 1 &amp; 2 antibody positivity

               -  CMV IgM positivity

               -  Hepatitis B infection

               -  GFR &lt; 45 ml/min/1.72 m2

               -  Albuminuria ≥ 1000 mg/24 hrs

               -  History of thrombosis or pulmonary embolism

               -  History of malignancy, tuberculosis or chronic viral hepatitis

               -  History of any other serious illness which could be relevant for the protocol

               -  Presence of clinical significant HLA antibodies

               -  Blood donation within one month prior to screening

               -  Symptoms and/or signs of infection, particularly (present or past) endocarditis,
                  osteomyelitis

               -  Any history of hepatic or neoplastic disease

               -  Any history of renal disease (except diabetes)

               -  Abnormal liver function tests and/or NMR of liver

               -  Hemoglobinopathy

               -  History of any illness that, in the opinion of the investigator, might confound
                  the results of the study or pose additional risks to the patient

               -  Use of illicit drugs or overconsumption of alcohol (&gt; 3 IU/day) or history of
                  drug or alcohol abuse

               -  Being legally incapacitated, having significant emotional problems at the time of
                  the study, or having a history of a psychiatric disorder that may be exacerbated
                  by the transplantation procedure or interfere with compliance during follow-up

               -  Having received antidepressant medications during the last 6 months

               -  Participating in another pharmacological study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Keymeulen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bart Keymeulen, MD PhD</last_name>
    <phone>+32 2 477 61 11</phone>
    <email>bart.keymeulen@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Hilbrands, MD PhD</last_name>
    <phone>+32 2 476 37 34</phone>
    <email>Robert.Hilbrands@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Keymeulen, MD PhD</last_name>
      <phone>+32 2 477 61 11</phone>
      <email>bart.keymeulen@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Bart Keymeulen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter , Gillard</last_name>
      <email>pieter.gillard@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Da Hae Lee, MD</last_name>
      <phone>+32 16 34 23 98</phone>
      <email>dahae.lee@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Pieter Gillard, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Gillard P, Keymeulen B, Mathieu C. Beta-cell transplantation in type 1 diabetic patients: a work in progress to cure. Verh K Acad Geneeskd Belg. 2010;72(1-2):71-98.</citation>
    <PMID>20726441</PMID>
  </reference>
  <reference>
    <citation>Hilbrands R, Huurman VA, Gillard P, Velthuis JH, De Waele M, Mathieu C, Kaufman L, Pipeleers-Marichal M, Ling Z, Movahedi B, Jacobs-Tulleneers-Thevissen D, Monbaliu D, Ysebaert D, Gorus FK, Roep BO, Pipeleers DG, Keymeulen B. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes. 2009 Oct;58(10):2267-76. doi: 10.2337/db09-0160. Epub 2009 Jul 14.</citation>
    <PMID>19602536</PMID>
  </reference>
  <reference>
    <citation>Gillard P, Vandemeulebroucke E, Keymeulen B, Pirenne J, Maes B, De Pauw P, Vanrenterghem Y, Pipeleers D, Mathieu C. Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients. Transplantation. 2009 Feb 15;87(3):402-7. doi: 10.1097/TP.0b013e3181928a1c.</citation>
    <PMID>19202446</PMID>
  </reference>
  <reference>
    <citation>Pipeleers D, Chintinne M, Denys B, Martens G, Keymeulen B, Gorus F. Restoring a functional beta-cell mass in diabetes. Diabetes Obes Metab. 2008 Nov;10 Suppl 4:54-62. doi: 10.1111/j.1463-1326.2008.00941.x. Review.</citation>
    <PMID>18834433</PMID>
  </reference>
  <reference>
    <citation>Keymeulen B. Therapies aimed at preservation or restoration of beta cell function in type 1 diabetes. Verh K Acad Geneeskd Belg. 2008;70(2):85-103. Review.</citation>
    <PMID>18630722</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>December 27, 2013</last_update_submitted>
  <last_update_submitted_qc>December 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ-VUB</investigator_affiliation>
    <investigator_full_name>Bart Keymeulen</investigator_full_name>
    <investigator_title>MD. PhD.</investigator_title>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Beta Cells</keyword>
  <keyword>Encapsulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

